Idioma:

FDA Panel Urges Caution on Many Anti-Inflammatory Drugs

Couzin, Jennifer

Science (American Association for the Advancement of Science), 2005-02, Vol.307 (5713), p.1183-1185 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
FDA Panel Urges Caution on Many Anti-Inflammatory Drugs
Autor: Couzin, Jennifer
Assuntos: Cancer ; Committees ; COX-2 inhibitors ; Drug use ; FDA approval ; Health aspects ; Heart attacks ; Heart Disorders ; Narcotics ; News of the Week ; Nonsteroidal anti-inflammatory drugs ; Patients ; Product defects and recalls ; Stroke
É parte de: Science (American Association for the Advancement of Science), 2005-02, Vol.307 (5713), p.1183-1185
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: At a 3-day meeting last week to hash out how a class of painkillers might trigger heart attacks and strokes, new puzzles emerged, even as two US Food and Drug Administration advisory committees agreed that use of the drugs, known as COX-2 inhibitors, be allowed but sharply curtailed. Wrestling with questions that affect millions of patients and billions of dollars in drug company revenue, the committees--on arthritis drugs and drug safety--voted in favor of keeping Celebrex, Bextra, and even Vioxx on the market but adding stringent warnings to them and possible other nonsteroidal anti-inflammatory drugs.
Editor: Washington: American Association for the Advancement of Science
Idioma: Inglês

Voltar para lista de resultados